JP2023506765A - 変化した表面残基を有する設計されたアンキリン反復ドメイン - Google Patents
変化した表面残基を有する設計されたアンキリン反復ドメイン Download PDFInfo
- Publication number
- JP2023506765A JP2023506765A JP2022535453A JP2022535453A JP2023506765A JP 2023506765 A JP2023506765 A JP 2023506765A JP 2022535453 A JP2022535453 A JP 2022535453A JP 2022535453 A JP2022535453 A JP 2022535453A JP 2023506765 A JP2023506765 A JP 2023506765A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- ankyrin repeat
- protein
- designed ankyrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Gynecology & Obstetrics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19215435 | 2019-12-11 | ||
| EP19215434.2 | 2019-12-11 | ||
| EP19215433.4 | 2019-12-11 | ||
| EP19215435.9 | 2019-12-11 | ||
| EP19215433 | 2019-12-11 | ||
| EP19215436 | 2019-12-11 | ||
| EP19215434 | 2019-12-11 | ||
| EP19215436.7 | 2019-12-11 | ||
| EP20161059 | 2020-03-04 | ||
| EP20161059.9 | 2020-03-04 | ||
| EP20181234 | 2020-06-19 | ||
| EP20181234.4 | 2020-06-19 | ||
| PCT/EP2020/085855 WO2021116462A1 (en) | 2019-12-11 | 2020-12-11 | Designed ankyrin repeat domains with altered surface residues |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023506765A true JP2023506765A (ja) | 2023-02-20 |
| JP2023506765A5 JP2023506765A5 (cg-RX-API-DMAC7.html) | 2023-12-18 |
Family
ID=73790118
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535453A Pending JP2023506765A (ja) | 2019-12-11 | 2020-12-11 | 変化した表面残基を有する設計されたアンキリン反復ドメイン |
| JP2022535443A Active JP7794740B2 (ja) | 2019-12-11 | 2020-12-11 | 組換えペプチド-mhc複合体結合タンパク質並びにそれらの生成及び使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535443A Active JP7794740B2 (ja) | 2019-12-11 | 2020-12-11 | 組換えペプチド-mhc複合体結合タンパク質並びにそれらの生成及び使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20220106707A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4073091A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023506765A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20220113491A (cg-RX-API-DMAC7.html) |
| CN (2) | CN115003689A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020402581A1 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112022011177A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3161321A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL293698A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022007122A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2021116469A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020402581A1 (en) | 2019-12-11 | 2022-06-23 | Molecular Partners Ag | Designed ankyrin repeat domains with altered surface residues |
| MX2022013945A (es) | 2020-05-06 | 2023-02-14 | Molecular Partners Ag | Nuevas proteinas de union a repeticiones de anquirina y sus usos. |
| IL298168A (en) | 2020-05-14 | 2023-01-01 | Molecular Partners Ag | Multispecific proteins |
| EP3957649A1 (en) * | 2020-08-18 | 2022-02-23 | Athebio AG | Improved n-terminal capping modules of ankyrin repeat domains |
| US11981710B2 (en) | 2020-08-18 | 2024-05-14 | Athebio Ag | N-terminal capping modules of ankyrin repeat domains |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| WO2022190016A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based multi-specific t-cell engagers |
| EP4387984A1 (en) * | 2021-08-17 | 2024-06-26 | Athebio AG | Variants of ankyrin repeat domains |
| WO2023021050A1 (en) * | 2021-08-17 | 2023-02-23 | Athebio Ag | Variants of ankyrin repeat domains |
| EP4137508A1 (en) * | 2021-08-17 | 2023-02-22 | Athebio AG | Variants of ankyrin repeat domains |
| WO2023110983A1 (en) | 2021-12-14 | 2023-06-22 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| CA3240046A1 (en) * | 2021-12-14 | 2023-06-22 | Cdr-Life Ag | Dual mhc-targeting t cell engager |
| CA3262553A1 (en) | 2022-08-01 | 2024-02-08 | Molecular Partners Ag | REHEARSAL AREAS DESIGNED WITH MODIFIED CHARGES AND THEIR USE |
| EP4587046A1 (en) | 2022-09-14 | 2025-07-23 | CDR-Life AG | Mage-a4 peptide dual t cell engagers |
| EP4673159A1 (en) | 2023-02-27 | 2026-01-07 | Molecular Partners AG | Darpins for use in reducing renal accumulation of drugs |
| EP4694904A2 (en) | 2023-04-13 | 2026-02-18 | REGENXBIO Inc. | Targeting aav capsids, methods of manufacturing and using same |
| WO2024251628A1 (en) * | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd16a binding proteins and their use |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
| WO2025163082A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Dll3-specific binding constructs and their use in radiotherapy |
| WO2025163144A1 (en) * | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Recombinant mesothelin binding proteins and their use |
| DE202024101891U1 (de) | 2024-04-16 | 2025-07-18 | Igus Gmbh | Leitungsführungsvorrichtung für Reinraumanwendungen sowie Halteelement dafür |
| WO2025250756A2 (en) * | 2024-05-30 | 2025-12-04 | Aethon Therapeutics, Inc. | Compositions and methods for binding to covalent peptide conjugates containing divarasib |
| WO2026093563A2 (en) | 2024-10-31 | 2026-05-07 | Molecular Partners Ag | Multispecific binding proteins and their use |
| WO2026150109A1 (en) | 2025-01-10 | 2026-07-16 | Molecular Partners Ag | Mesothelin-specific binding constructs and their use in radiotherapy |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2738180A1 (en) * | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| JP2014519808A (ja) * | 2011-04-29 | 2014-08-21 | ヤンセン バイオテツク,インコーポレーテツド | Il4/il13に結合する反復タンパク質及び使用 |
| WO2016023898A2 (en) * | 2014-08-11 | 2016-02-18 | Medimmune Limited | Intracellular antigen binding |
| JP2018511327A (ja) * | 2015-04-02 | 2018-04-26 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 血清アルブミンに対する結合特異性を有する設計アンキリンリピートドメイン |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| KR20070085314A (ko) | 2004-11-12 | 2007-08-27 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 재조합 뉴캐슬 질환 바이러스 |
| KR101268939B1 (ko) | 2005-07-08 | 2013-05-30 | 유니버시티 오브 취리히 | 융합 폴리펩티드의 공번역 전좌를 사용한 파아지디스플레이 |
| HUE025636T2 (en) | 2007-07-27 | 2016-04-28 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
| CA2700391A1 (en) | 2007-09-24 | 2009-04-02 | University Of Zuerich | Designed armadillo repeat proteins |
| NZ592591A (en) | 2008-11-03 | 2012-04-27 | Molecular Partners Ag | Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制vegf-a受體交互作用的經修飾結合性蛋白質 |
| EP3514169B1 (en) | 2010-11-26 | 2024-03-06 | Molecular Partners AG | Designed repeat proteins binding to serum albumin |
| SG11201408196RA (en) | 2012-06-28 | 2015-03-30 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| EP2906591A1 (en) | 2012-10-15 | 2015-08-19 | Universität Zürich | Bispecific her2 ligands for cancer therapy |
| US11453708B2 (en) | 2013-05-31 | 2022-09-27 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
| ES2740930T3 (es) | 2014-03-14 | 2020-02-07 | Immunocore Ltd | Bibliotecas de TCR |
| EP3286222A4 (en) | 2015-03-23 | 2018-08-08 | The Johns Hopkins University | Hla-restricted epitopes encoded by somatically mutated genes |
| JP7599819B2 (ja) | 2016-06-02 | 2024-12-16 | イムノコア リミテッド | gp100特異的TCR-抗CD3 scFv融合タンパク質の投薬レジメン |
| MY196882A (en) | 2016-09-22 | 2023-05-08 | Molecular Partners Ag | Recombinant binding proteins and their use |
| US12065479B2 (en) * | 2017-11-16 | 2024-08-20 | The Regents Of The University Of California | Force sensor cleavage domain containing chimeric polypeptides and methods of use thereof |
| CA3139164A1 (en) | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| EP3980452A1 (en) | 2019-06-04 | 2022-04-13 | Molecular Partners AG | Recombinant 4-1bb binding proteins and their use |
| JP2022535564A (ja) | 2019-06-04 | 2022-08-09 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 多選択性タンパク質 |
| KR20220016944A (ko) | 2019-06-04 | 2022-02-10 | 몰리큘라 파트너스 아게 | 개선된 안정성을 갖는 설계된 안키린 반복 도메인 |
| CN114945584A (zh) | 2019-12-11 | 2022-08-26 | 分子合作伙伴股份公司 | 重组肽-mhc复合物结合蛋白及其生成和用途 |
| AU2020402581A1 (en) * | 2019-12-11 | 2022-06-23 | Molecular Partners Ag | Designed ankyrin repeat domains with altered surface residues |
| MX2022013945A (es) * | 2020-05-06 | 2023-02-14 | Molecular Partners Ag | Nuevas proteinas de union a repeticiones de anquirina y sus usos. |
| IL298168A (en) | 2020-05-14 | 2023-01-01 | Molecular Partners Ag | Multispecific proteins |
| AU2021271131A1 (en) | 2020-05-14 | 2022-12-15 | Molecular Partners Ag | Recombinant CD40 binding proteins and their use |
-
2020
- 2020-12-11 AU AU2020402581A patent/AU2020402581A1/en not_active Abandoned
- 2020-12-11 KR KR1020227023763A patent/KR20220113491A/ko not_active Withdrawn
- 2020-12-11 EP EP20821220.9A patent/EP4073091A1/en active Pending
- 2020-12-11 JP JP2022535453A patent/JP2023506765A/ja active Pending
- 2020-12-11 KR KR1020227023764A patent/KR20220113492A/ko not_active Withdrawn
- 2020-12-11 CA CA3161321A patent/CA3161321A1/en active Pending
- 2020-12-11 IL IL293698A patent/IL293698A/en unknown
- 2020-12-11 CA CA3161326A patent/CA3161326A1/en active Pending
- 2020-12-11 EP EP20821221.7A patent/EP4073092A2/en not_active Withdrawn
- 2020-12-11 CN CN202080093076.7A patent/CN115003689A/zh active Pending
- 2020-12-11 WO PCT/EP2020/085863 patent/WO2021116469A2/en not_active Ceased
- 2020-12-11 BR BR112022011177A patent/BR112022011177A2/pt not_active Application Discontinuation
- 2020-12-11 CN CN202080093012.7A patent/CN114929730A/zh active Pending
- 2020-12-11 WO PCT/EP2020/085855 patent/WO2021116462A1/en not_active Ceased
- 2020-12-11 IL IL293704A patent/IL293704A/en unknown
- 2020-12-11 BR BR112022011456A patent/BR112022011456A2/pt not_active Application Discontinuation
- 2020-12-11 JP JP2022535443A patent/JP7794740B2/ja active Active
- 2020-12-11 MX MX2022007122A patent/MX2022007122A/es unknown
- 2020-12-11 MX MX2022007120A patent/MX2022007120A/es unknown
- 2020-12-11 AU AU2020399230A patent/AU2020399230A1/en not_active Abandoned
-
2021
- 2021-08-02 US US17/392,204 patent/US20220106707A1/en not_active Abandoned
- 2021-08-12 US US17/400,471 patent/US11578427B2/en active Active
-
2023
- 2023-01-12 US US18/153,576 patent/US12435445B2/en active Active
- 2023-02-24 US US18/174,086 patent/US20230243070A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014519808A (ja) * | 2011-04-29 | 2014-08-21 | ヤンセン バイオテツク,インコーポレーテツド | Il4/il13に結合する反復タンパク質及び使用 |
| EP2738180A1 (en) * | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| WO2016023898A2 (en) * | 2014-08-11 | 2016-02-18 | Medimmune Limited | Intracellular antigen binding |
| JP2018511327A (ja) * | 2015-04-02 | 2018-04-26 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 血清アルブミンに対する結合特異性を有する設計アンキリンリピートドメイン |
Non-Patent Citations (1)
| Title |
|---|
| ORF NAMES:A2143_11365: "A0A1G0DY05" [ONLINE], vol. XP055732096, JPN6024045969, 2017, ISSN: 0005462558 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230243070A1 (en) | 2023-08-03 |
| CA3161321A1 (en) | 2021-06-17 |
| KR20220113491A (ko) | 2022-08-12 |
| EP4073091A1 (en) | 2022-10-19 |
| WO2021116462A1 (en) | 2021-06-17 |
| JP2023506757A (ja) | 2023-02-20 |
| US11578427B2 (en) | 2023-02-14 |
| US20220064234A1 (en) | 2022-03-03 |
| CN114929730A (zh) | 2022-08-19 |
| IL293698A (en) | 2022-08-01 |
| WO2021116469A3 (en) | 2021-12-02 |
| KR20220113492A (ko) | 2022-08-12 |
| AU2020402581A1 (en) | 2022-06-23 |
| US12435445B2 (en) | 2025-10-07 |
| AU2020399230A1 (en) | 2022-06-23 |
| US20220106707A1 (en) | 2022-04-07 |
| CN115003689A (zh) | 2022-09-02 |
| AU2020402581A9 (en) | 2022-07-14 |
| EP4073092A2 (en) | 2022-10-19 |
| US20230340698A1 (en) | 2023-10-26 |
| BR112022011456A2 (pt) | 2022-08-23 |
| MX2022007120A (es) | 2022-09-09 |
| BR112022011177A2 (pt) | 2022-09-27 |
| MX2022007122A (es) | 2022-09-09 |
| WO2021116469A2 (en) | 2021-06-17 |
| CA3161326A1 (en) | 2021-06-17 |
| JP7794740B2 (ja) | 2026-01-06 |
| IL293704A (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12435445B2 (en) | Designed ankyrin repeat domains with altered surface residues | |
| AU2011333665B2 (en) | Designed repeat proteins binding to serum albumin | |
| TWI508736B (zh) | 結合至il-23之以纖維連接蛋白為主之架構域蛋白質 | |
| EP2867360B1 (en) | Designed ankyrin repeat proteins binding to platelet-derived growth factor | |
| EP3004152B1 (en) | Designed ankyrin repeat proteins binding to hepatocyte growth factor | |
| CN103068843B (zh) | 结合pcsk9的基于纤连蛋白的支架域蛋白质 | |
| CN104470944B (zh) | 非天然共有白蛋白结合结构域 | |
| KR102461666B1 (ko) | 혈청 알부민 결합 피브로넥틴 iii 형 도메인 | |
| CN114206908B (zh) | 具有改善的稳定性的经设计的锚蛋白重复结构域 | |
| WO2018230257A1 (ja) | IgG結合ペプチド、及び該ペプチドによる抗体の特異的修飾 | |
| JP6738340B2 (ja) | 新規なegfr結合タンパク質 | |
| US20220348624A1 (en) | Recombinant interleukin-15 analog | |
| IL303152A (en) | Compositions and methods for selective depletion of target molecules | |
| KR102723629B1 (ko) | 기능성폴리펩티드 변이체의 컨쥬게이트 및 그 용도 | |
| WO2016167291A1 (ja) | 環状化サイトカイン及びその製法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231208 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241119 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250207 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250417 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250514 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250812 |